摘要
目的探讨瑞替普酶对急性ST段抬高性心肌梗死溶栓治疗的临床效果。方法选择急性ST段抬高性心肌梗死患者26例。诊断符合AHA/ACC的AMI诊断标准,且无溶栓禁忌证。所有入选患者都给予吸氧、镇静、监护、卧床休息、建立静脉通路等基本处理下,另建一静脉通路,取瑞替普酶溶栓。结果溶栓后再通24例,溶栓不良反应2例,2周内死亡1例,半年内发生心绞痛8例,半年内再入院2例。结论瑞替普酶对急性ST段抬高性心肌梗死溶栓治疗临床效果显著,在不具备介入治疗条件下的基层医院溶栓是最佳选择,可最大限度挽救生命。
Objective To investigate the efficacy of reteplase thrombolytic therapy for acute ST-segment elevation myocardial infarction （ASTEMI）. Methods Twenty-six cases of ASTEMI diagnosed by AHA/ACC AMI criteria and with none thrombolytic contraindications. All patients were given oxygen, sedation, guardianship, bed rest, establish intravenous access. Construct a new venous access for reteplase thrombolytic therapy. Results Twenty-four cases recanalization, two cases of adverse reactions, one case died within two weeks, eight cases of angina within six months, two cases of readmission within six months. Conclusion Reteplase thrombolytic therapy makes significant clinical efficacy for ASTEMI patients. In the primary hospital with none interventional therapy conditions, thrombolytic therapy can be regarded as the best choice and reduce mortality to the maximum extent.
出处
《中国当代医药》
2013年第1期77-78,共2页
China Modern Medicine
关键词
ST段抬高性心肌梗死
瑞替普酶
溶栓治疗
疗效观察
ST-segment elevation myocardial infarction （STEMI）
Reteplase
Thrombolytic therapy
Efficacy observation
